Cargando…
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions
Antiblastic drugs have a high number of potential side-effects. Paradoxically, according to the National Network of Pharmacovigilance, the number of reported adverse reactions to these agents is proportionally lower than that registered for non antiblastic drugs. Critical phenomena such as treatment...
Autores principales: | Gardini, Andrea Casadei, Tenti, Elena, Masini, Carla, Nanni, Oriana, Scarpi, Emanuela, Valgiusti, Martina, Restuccia, Silvia, Gallani, Maria Laura, Palazzini, Simonetta, Bianchini, Erica, Menozzi, Silvia, Maugeri, Antonio, Amadori, Dino, Minguzzi, Martina, Frassineti, Giovanni Luca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5130038/ https://www.ncbi.nlm.nih.gov/pubmed/27119511 http://dx.doi.org/10.18632/oncotarget.8942 |
Ejemplares similares
-
IL-8 and thrombospondin-1 as prognostic markers in patients with metastatic colorectal cancer receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2018) -
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
por: Marisi, Giorgia, et al.
Publicado: (2017) -
Right- vs. Left-Sided Metastatic Colorectal Cancer: Differences in Tumor Biology and Bevacizumab Efficacy
por: Ulivi, Paola, et al.
Publicado: (2017) -
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016) -
Chemotherapy and palliative care near end-of life: examining the appropriateness at a cancer institute for colorectal cancer patients
por: Massa, Ilaria, et al.
Publicado: (2018)